This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEXINGTON, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of vaccines for cancer and infectious diseases, today announced that Garo Armen, Ph.D, chairman and CEO of Agenus, will present a corporate overview at two upcoming conferences. They include the NewsMakers in the Biotech Industry Conference on Friday, September 7
th at 2:30 pm ET at the Millennium Broadway Hotel & Conference Center in NYC and the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10
th at 4:05 pm ET at the Waldorf=Astoria hotel, NYC.
Web Cast Information
The live and archived webcast of the company presentation will be accessible from the company's website at
www.agenusbio.com/webcast . Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Agenus website for one month following the conference.
Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. For more information, please visit
The Agenus logo is available at
There are 16 QS-21 Stimulon
®1 adjuvant containing vaccine programs in clinical development. Between Agenus and its partners, there are a total of 18 programs in clinical development. They include:
Phase 3: GSK's RTS,S for malaria 2
Phase 3: GSK's MAGE-A3 cancer immunotherapy for selected patients with resected melanoma 2
Phase 3: GSK's MAGE-A3 cancer immunotherapy for selected patients with resected non-small cell lung cancer 2
Phase 3: GSK's HZ/su for shingles 2
Agenus' pipeline programs include:
Phase 2: Prophage Series G-100 for newly diagnosed glioma
Phase 2: Prophage Series G-200 for recurrent glioma
Phase 2-Ready: HerpV (contains QS-21) for genital herpes
Saponin Platform: QS-21 Stimulon®Adjuvant
QS-21 licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy. Agenus is generally entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.